• Yuxian Lin, Xiaowei Zheng, QiuJie Chen, and Ruibin Wu.
• Department of Ophthalmology, The First Affiliated Hospital of Shantou University Medical College, Guangdong, China.
• Medicine (Baltimore). 2021 Apr 30; 100 (17): e25682e25682.

BackgroundThe argument on the optimal treatment for patients with proliferative diabetic retinopathy (PDR) remains to be resolved. Therefore, the primary objective of the present study was to evaluate the clinical efficacy of anti-vascular endothelial growth factor (anti-VEGF) therapy versus panretinal photocoagulation (PRP) for patients with PDR.MethodsTwo independent investigators followed The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and the recommendations of the Cochrane Collaboration to conduct this meta-analysis. The electronic databases of EMBASE, PubMed, Cochrane Library, and Web of Science were searched from the inception to April 2021 using the following key terms: "proliferative diabetic retinopathy," "anti-vascular endothelial growth factor," and "panretinal photocoagulation," for all relevant studies. We identified literature that met the following inclusion criteria: patients with PDR; studies focusing on assessing anti-VEGF therapy and PRP; the following outcome measures must be shown: anatomical outcomes, including complete regression and recurrence of neovascularization, mean change in best corrected vision acuity from baseline to the end of follow-up period. The Cochrane risk of bias tool was used to evaluate the risk of bias of included randomized clinical trials by 2 independent reviewers.ResultsThis protocol will provide a reliable theoretical basis for the following research.Trial Registration Number10.17605/OSF.IO/UHYDR.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…